Inhibition of intestinal FXR activity as a possible mechanism for the beneficial effects of a probiotic mix supplementation on lipid metabolism alterations and weight gain in mice fed a high fat diet

References

• Myers J, Kokkinos P, Nyelin E. Physical activity, cardiorespiratory fitness, and the metabolic syndrome. Nutrients. 2019;11(7):1652. doi:10.3390/nu11071652.
   PubMed Web of Science ®Google Scholar
• Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. doi:10.1007/s11906-018-0812-z.
   PubMed Web of Science ®Google Scholar
• Kopp W. How western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes, Metab Syndr Obes Targets Ther. 2019;12:2221–21. doi:10.2147/DMSO.S216791.
   PubMed Web of Science ®Google Scholar
• Després JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature. 2006;444(7121):881–887. doi:10.1038/nature05488.
   PubMed Web of Science ®Google Scholar
• Malesza IJ, Malesza M, Walkowiak J, Mussin N, Walkowiak D, Aringazina R, Bartkowiak-Wieczorek J, Mądry E. High-fat, Western-style diet, systemic inflammation, and gut microbiota: a narrative review. Cells. 2021;10(11):3164. doi:10.3390/cells10113164.
   PubMed Web of Science ®Google Scholar
• Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. Gut. 2021;70(6):1174–1182. doi:10.1136/gutjnl-2020-323071.
   PubMed Web of Science ®Google Scholar
• Boulangé CL, Neves AL, Chilloux J, Nicholson JK, Dumas ME. Impact of the gut microbiota on inflammation, obesity, and metabolic disease. Genome Med. 2016;8(1):42. doi:10.1186/s13073-016-0303-2.
   PubMedGoogle Scholar
• Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–1031. doi:10.1038/nature05414.
   PubMed Web of Science ®Google Scholar
• de Groot P, Scheithauer T, Bakker GJ, Prodan A, Levin E, Tanweer Khan M, Herrema H, Ackermans M, Serlie MJM, de Brauw M, et al. Donor metabolic characteristics drive effects of faecal microbiota transplantation on recipient insulin sensitivity, energy expenditure and intestinal transit time. Gut. 2020;69(3):502. doi:10.1136/gutjnl-2019-318320.
   PubMed Web of Science ®Google Scholar
• Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Sci. 2013;341(6150):1241214. doi:10.1126/science.1241214.
   PubMed Web of Science ®Google Scholar
• Kamada N, Seo SU, Chen GY, Núñez G. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 2013;13(5):321–335. doi:10.1038/nri3430.
   PubMed Web of Science ®Google Scholar
• Serino M, Luche E, Gres S, Baylac A, Bergé M, Cenac C, Waget A, Klopp P, Iacovoni J, Klopp C, et al. Metabolic adaptation to a high-fat diet is associated with a change in the gut microbiota. Gut. 2012;61(4):543–553. doi:10.1136/gutjnl-2011-301012.
   PubMed Web of Science ®Google Scholar
• Jansma J, Brinkman F, Van Hemert S, El Aidy S. Targeting the endocannabinoid system with microbial interventions to improve gut integrity. Prog Neuropsychopharmacol Biol Psychiatry. 2021;106:110169. doi:10.1016/j.pnpbp.2020.110169.
   PubMed Web of Science ®Google Scholar
• Álvarez-Arraño V, Martín-Peláez S. Effects of probiotics and synbiotics on weight loss in subjects with overweight or obesity: a systematic review. Nutr. 2021;13(10):3627. doi:10.3390/nu13103627.
   Google Scholar
• Famouri F, Shariat Z, Hashemipour M, Keikha M, Kelishadi R. Effects of probiotics on nonalcoholic fatty liver disease in obese children and adolescents. J Pediatr Gastroenterol Nutr. 2017;64(3):413–417. doi:10.1097/MPG.0000000000001422.
   PubMed Web of Science ®Google Scholar
• Duseja A, Acharya SK, Mehta M, Chhabra S, Shalimar R, Das S, Dattagupta A, Dhiman S, Chawla YK. High potency multistrain probiotic improves liver histology in non-alcoholic fatty liver disease (NAFLD): a randomised, double-blind, proof of concept study. BMJ Open Gastroenterol. 2019;6(1):e000315. doi:10.1136/bmjgast-2019-000315.
   PubMed Web of Science ®Google Scholar
• Ahn HY, Kim M, Chae JS, Ahn YT, Sim JH, Choi ID, Lee SH, Lee JH. Supplementation with two probiotic strains, lactobacillus curvatus HY7601 and lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia. Atheroscleros. 2015;241(2):649–656. doi:10.1016/j.atherosclerosis.2015.06.030.
   PubMed Web of Science ®Google Scholar
• Xavier-Santos D, Bedani R, Lima ED, Saad SMI. Impact of probiotics and prebiotics targeting metabolic syndrome. J Funct Foods. 2020;64:103666. doi:10.1016/j.jff.2019.103666.
   Web of Science ®Google Scholar
• Le Barz M, Daniel N, Varin TV, Naimi S, Demers-Mathieu V, Pilon G, Audy J, Laurin É, Roy D, Urdaci MC, et al. In vivo screening of multiple bacterial strains identifies lactobacillus rhamnosus Lb102 and bifidobacterium animalis ssp. lactis Bf141 as probiotics that improve metabolic disorders in a mouse model of obesity. FASEB J Off Publ Fed Am Soc Exp Biol. 2019;33(4):4921–4935. doi:10.1096/fj.201801672R.
   PubMed Web of Science ®Google Scholar
• Alard J, Cudennec B, Boutillier D, Peucelle V, Descat A, Decoin R, Kuylle S, Jablaoui A, Rhimi M, Wolowczuk I, et al. Multiple selection criteria for probiotic strains with high potential for obesity management. Nutr. 2021;13(3):713. doi:10.3390/nu13030713.
   Google Scholar
• Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The controversial role of human gut Lachnospiraceae. Microorgan. 2020;8(4):573. doi:10.3390/microorganisms8040573.
   PubMed Web of Science ®Google Scholar
• Li Q, Chang Y, Zhang K, Chen H, Tao S, Zhang Z. Implication of the gut microbiome composition of type 2 diabetic patients from northern China. Sci Rep. 2020;10(1):5450. doi:10.1038/s41598-020-62224-3.
   PubMed Web of Science ®Google Scholar
• Kusada H, Kameyama K, Meng XY, Kamagata Y, Tamaki H. Fusimonas intestini gen. Nov., sp. Nov., a novel intestinal bacterium of the family lachnospiraceae associated with diabetes in mice. Sci Rep. 2017;7(1):18087. doi:10.1038/s41598-017-18122-2.
   PubMedGoogle Scholar
• Park S, Zhang T, Kang S. Fecal microbiota composition, their interactions, and metagenome function in US adults with type 2 diabetes according to enterotypes. Int J Mol Sci. 2023;24(11):9533. doi:10.3390/ijms24119533.
   PubMed Web of Science ®Google Scholar
• Simon MC, Strassburger K, Nowotny B, Kolb H, Nowotny P, Burkart V, Zivehe F, Hwang JH, Stehle P, Pacini G, et al. Intake of Lactobacillus reuteri improves incretin and insulin secretion in glucose-tolerant humans: a proof of concept. Diab Care. 2015;38(10):1827–1834. 10.2337/dc14–2690. doi:10.2337/dc14-2690.
   Web of Science ®Google Scholar
• Natividad JM, Agus A, Planchais J, Lamas B, Jarry AC, Martin R, Michel ML, Chong-Nguyen C, Roussel R, Straube M, et al. Impaired aryl hydrocarbon receptor ligand production by the gut microbiota is a key factor in metabolic syndrome. Cell Metab. 2018;28(5):737–749.e4. doi:10.1016/j.cmet.2018.07.001.
   PubMed Web of Science ®Google Scholar
• Zhang C, Fang R, Lu X, Zhang Y, Yang M, Su Y, Jiang Y, Man C. Lactobacillus reuteri J1 prevents obesity by altering the gut microbiota and regulating bile acid metabolism in obese mice. Food Funct. 2022;13(12):6688–6701. doi:10.1039/D1FO04387K.
   PubMed Web of Science ®Google Scholar
• Lopez-Escalera S, Lund ML, Hermes GDA, Choi BSY, Sakamoto K, Wellejus A. In vitro screening for probiotic properties of lactobacillus and bifidobacterium strains in assays relevant for non-alcoholic fatty liver disease prevention. Nutr. 2023;15(10):2361. doi:10.3390/nu15102361.
   Google Scholar
• Dörnyei G, Vass Z, Juhász CB, Nádasy GL, Hunyady L, Szekeres M. Role of the endocannabinoid system in metabolic control processes and in the pathogenesis of metabolic syndrome: an update. Biomed. 2023;11(2):306. doi:10.3390/biomedicines11020306.
   Google Scholar
• Sun L, Cai J, Gonzalez FJ. The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer. Nat Rev Gastroenterol Hepatol. 2021;18(5):335–347. doi:10.1038/s41575-020-00404-2.
   PubMed Web of Science ®Google Scholar
• Gérard C, Vidal H. Impact of gut microbiota on host glycemic control. Front Endocrinol. 2019;10:29. doi:10.3389/fendo.2019.00029.
   PubMed Web of Science ®Google Scholar
• McFarland LV, Evans CT, Goldstein EJC. Strain-specificity and disease-specificity of probiotic efficacy: a systematic review and meta-analysis. Front Med. 2018;5:124. doi:10.3389/fmed.2018.00124.
   PubMed Web of Science ®Google Scholar
• Park SS, Lee YJ, Kang H, Yang G, Hong EJ, Lim JY, Oh S, Kim E. Lactobacillus amylovorus KU4 ameliorates diet-induced obesity in mice by promoting adipose browning through PPARγ signaling. Sci Rep. 2019;9(1):20152. doi:10.1038/s41598-019-56817-w.
   PubMed Web of Science ®Google Scholar
• Camilleri M. Human intestinal barrier: effects of stressors, diet, prebiotics, and probiotics. Clin Transl Gastroenterol. 2021;12(1):e00308. doi:10.14309/ctg.0000000000000308.
   PubMed Web of Science ®Google Scholar
• Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM, Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761–1772. doi:10.2337/db06-1491.
   PubMed Web of Science ®Google Scholar
• Chaiyasut C, Sivamaruthi BS, Lailerd N, Sirilun S, Khongtan S, Fukngoen P, Peerajan S, Saelee M, Chaiyasut K, Kesika P, et al. Probiotics supplementation improves intestinal permeability, obesity index and metabolic biomarkers in elderly Thai subjects: a randomized controlled trial. Foods. 2022;11(3):268. doi:10.3390/foods11030268.
   PubMed Web of Science ®Google Scholar
• Teixeira TFS, Collado MC, Ferreira CLLF, Bressan J, Peluzio MDCG. Potential mechanisms for the emerging link between obesity and increased intestinal permeability. Nutr Res. 2012;32(9):637–647. doi:10.1016/j.nutres.2012.07.003.
   PubMed Web of Science ®Google Scholar
• Markowiak-Kopeć P, Śliżewska K. The effect of probiotics on the production of short-chain fatty acids by human intestinal microbiome. Nutr. 2020;12(4):1107. doi:10.3390/nu12041107.
   Google Scholar
• Kraatz M, Wallace RJ, Svensson L. Olsenella umbonata sp. Nov., a microaerotolerant anaerobic lactic acid bacterium from the sheep rumen and pig jejunum, and emended descriptions of olsenella, olsenella uli and olsenella profusa. Int J Syst Evol Microbiol. 2011;61:795–803. doi:10.1099/ijs.0.022954-0.
   PubMed Web of Science ®Google Scholar
• Sakamoto M, Iino T, Yuki M, Ohkuma M. Lawsonibacter asaccharolyticus gen. Nov., sp. Nov., a butyrate-producing bacterium isolated from human faeces. Int J Syst Evol Microbiol. 2018;68:2074–2081. doi:10.1099/ijsem.0.002800.
   PubMed Web of Science ®Google Scholar
• Morotomi M, Nagai F, Watanabe Y. Description of christensenella minuta gen. Nov., sp. Nov., isolated from human faeces, which forms a distinct branch in the order clostridiales, and proposal of christensenellaceae fam. nov. Int J Syst Evol Microbiol. 2012;62:144–149. doi:10.1099/ijs.0.026989-0.
   PubMed Web of Science ®Google Scholar
• Nie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X. Roseburia intestinalis: a beneficial gut organism from the discoveries in genus and species. Front Cell Infect Microbiol. 2021;11:757718. doi:10.3389/fcimb.2021.757718.
   PubMed Web of Science ®Google Scholar
• Lagkouvardos I, Pukall R, Abt B, Foesel BU, Meier-Kolthoff JP, Kumar N, Bresciani A, Martínez I, Just S, Ziegler C, et al. The mouse intestinal bacterial collection (miBC) provides host-specific insight into cultured diversity and functional potential of the gut microbiota. Nature Microbiol. 2016;1(10):16131. doi:10.1038/nmicrobiol.2016.131.
   PubMed Web of Science ®Google Scholar
• Müller M, Hernández MAG, Goossens GH, Reijnders D, Holst JJ, Jocken JWE, Van Eijk H, Canfora EE, Blaak EE. Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans. Sci Rep. 2019;9(1):12515. doi:10.1038/s41598-019-48775-0.
   PubMedGoogle Scholar
• Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, Diakogiannaki E, Cameron J, Grosse J, Reimann F, Gribble FM. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein–coupled receptor FFAR2. Diabetes. 2012;61(2):364–371. doi:10.2337/db11-1019.
   PubMed Web of Science ®Google Scholar
• Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA. 2013;110(22):9066–9071. doi:10.1073/pnas.1219451110.
   PubMed Web of Science ®Google Scholar
• Sonne DP. MECHANISMS in ENDOCRINOLOGY: FXR signalling: a novel target in metabolic diseases. Eur J Endocrinol. 2021;184:R193–R205. doi:10.1530/EJE-20-1410.
   PubMed Web of Science ®Google Scholar
• Jahn D, Rau M, Hermanns HM, Geier A. Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. Cytokine Growth Factor Rev. 2015;26:625–635. doi:10.1016/j.cytogfr.2015.07.016.
   PubMed Web of Science ®Google Scholar
• Kir S, Beddow SA, Samuel VT, Miller P, Previs SF, Suino-Powell K, Xu HE, Shulman GI, Kliewer SA, Mangelsdorf DJ. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Sci. 2011;331:1621–1624. doi:10.1126/science.1198363.
   PubMed Web of Science ®Google Scholar
• Xie C, Jiang C, Shi J, Gao X, Sun D, Sun L, Wang T, Takahashi S, Anitha M, Krausz KW, et al. An intestinal farnesoid X receptor–ceramide signaling axis modulates hepatic gluconeogenesis in mice. Diabetes. 2017;66(3):613–626. doi:10.2337/db16-0663.
   PubMed Web of Science ®Google Scholar
• Li F, Jiang C, Krausz KW, Li Y, Albert I, Hao H, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun. 2013;4(1):2384. doi:10.1038/ncomms3384.
   PubMedGoogle Scholar
• Clifford BL, Sedgeman LR, Williams KJ, Morand P, Cheng A, Jarrett KE, Chan AP, Brearley-Sholto MC, Wahlström A, Ashby JW, et al. FXR activation protects against NAFLD via bile-acid-dependent reductions in lipid absorption. Cell Metab. 2021;33(8):1671–1684.e4. doi:10.1016/j.cmet.2021.06.012.
   PubMed Web of Science ®Google Scholar
• Jiang C, Xie C, Li F, Zhang L, Nichols RG, Krausz KW, Cai J, Qi Y, Fang Z-Z, Takahashi S, Tanaka, N., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J Clin Invest. 2015;125(1):386–402. doi:10.1172/JCI76738.
   PubMed Web of Science ®Google Scholar
• Huang M, Kong B, Zhang M, Rizzolo D, Armstrong LE, Schumacher JD, Chow MD, Lee YH, Joseph LB, Stofan M, et al. Enhanced alcoholic liver disease in mice with intestine-specific farnesoid X receptor deficiency. Lab Invest. 2020;100:1158–1168. doi:10.1038/s41374-020-0439-y.
   PubMed Web of Science ®Google Scholar
• Gonzalez FJ, Jiang C, Patterson AD. An intestinal microbiota–farnesoid X receptor axis modulates metabolic disease. Gastroenterol. 2016;151(5):845–859. doi:10.1053/j.gastro.2016.08.057.
   PubMed Web of Science ®Google Scholar
• Sun L, Xie C, Wang G, Wu Y, Wu Q, Wang X, Liu J, Deng Y, Xia J, Chen B, et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin. Nat Med. 2018;24(12):1919–1929. doi:10.1038/s41591-018-0222-4.
   PubMed Web of Science ®Google Scholar
• Bravard A, Gérard C, Defois C, Benoit B, Makki K, Meugnier E, Rainteau D, Rieusset J, Godet M, Vidal H. Metformin treatment for 8 days impacts multiple intestinal parameters in high-fat high-sucrose fed mice. Sci Rep. 2021;11(1):16684. doi:10.1038/s41598-021-95117-0.
   PubMed Web of Science ®Google Scholar
• Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the fxr-Fgf15 axis in mice. Cell Rep. 2014;7:12–18. doi:10.1016/j.celrep.2014.02.032.
   PubMed Web of Science ®Google Scholar
• Ganji-Arjenaki M, Rafieian-Kopaei M. Probiotics are a good choice in remission of inflammatory bowel diseases: a meta analysis and systematic review. J Cell Physiol. 2018;233:2091–2103. doi:10.1002/jcp.25911.
   PubMed Web of Science ®Google Scholar
• Cheng FS, Pan D, Chang B, Jiang M, Sang LX. Probiotic mixture VSL#3: an overview of basic and clinical studies in chronic diseases. World J Clin Cases. 2020;8:1361–1384. doi:10.12998/wjcc.v8.i8.1361.
   PubMed Web of Science ®Google Scholar
• Osterberg KL, Boutagy NE, McMillan RP, Stevens JR, Frisard MI, Kavanaugh JW, Davy BM, Davy KP, Hulver MW. Probiotic supplementation attenuates increases in body mass and fat mass during high-fat diet in healthy young adults: probiotic supplementation during high-fat diet. Obesity. 2015;23(12):2364–2370. doi:10.1002/oby.21230.
   PubMed Web of Science ®Google Scholar
• Liang X, Zhang Z, Zhou X, Lu Y, Li R, Yu Z, Tong L, Gong P, Yi H, Liu T, Zhang, L., et al. Probiotics improved hyperlipidemia in mice induced by a high cholesterol diet via downregulating FXR. Food Funct. 2020;11(11):9903–9911. doi:10.1039/D0FO02255A.
   PubMed Web of Science ®Google Scholar
• Wang Y, Xing X, Ma Y, Fan Y, Zhang Y, Nan B, Li X, Wang Y, Liu J. Prevention of high-fat-diet-induced dyslipidemia by lactobacillus plantarum LP104 through mediating bile acid enterohepatic axis circulation and intestinal flora. J Agric Food Chem. 2023;71(19):7334–7347. doi:10.1021/acs.jafc.2c09151.
   PubMed Web of Science ®Google Scholar
• Naville D, Gaillard G, Julien B, Vega N, Pinteur C, Chanon S, Vidal H, Le Magueresse-Battistoni B. Chronic exposure to a pollutant mixture at low doses led to tissue-specific metabolic alterations in male mice fed standard and high-fat high-sucrose diet. Chemosphere. 2019;220:1187–1199. doi:10.1016/j.chemosphere.2018.12.177.
   PubMed Web of Science ®Google Scholar
• Humbert L, Maubert MA, Wolf C, Duboc H, Mahé M, Farabos D, Seksik P, Mallet JM, Trugnan G, Masliah J, et al. Bile acid profiling in human biological samples: comparison of extraction procedures and application to normal and cholestatic patients. J Chromatogr B Analyt Technol Biomed Life Sci. 2012;899:135–145. doi:10.1016/j.jchromb.2012.05.015.
   PubMed Web of Science ®Google Scholar
• Robert C, Buisson C, Laugerette F, Abrous H, Rainteau D, Humbert L, Vande Weghe J, Meugnier E, Loizon E, Caillet F, et al. Impact of rapeseed and soy lecithin on postprandial lipid metabolism, bile acid profile, and gut bacteria in mice. Mol Nutr Food Res. 2021;65(9):2001068. doi:10.1002/mnfr.202001068.
   Web of Science ®Google Scholar